Morgan Stanley’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $872M | Buy |
1,397,712
+78,383
| +6% | +$53.4M | 0.05% | 362 |
|
|
2026
Q1 | $1.02B | Sell |
1,319,329
-69,994
| -5% | -$53.6M | 0.06% | 280 |
|
|
2025
Q4 | $1.07B | Sell |
1,389,323
-61,649
| -4% | -$41.9M | 0.06% | 271 |
|
|
2025
Q3 | $816M | Buy |
1,450,972
+163,309
| +13% | +$92.3M | 0.05% | 358 |
|
|
2025
Q2 | $676M | Buy |
1,287,663
+36,709
| +3% | +$20.5M | 0.04% | 402 |
|
|
2025
Q1 | $793M | Sell |
1,250,954
-179,416
| -13% | -$123M | 0.06% | 319 |
|
|
2024
Q4 | $1.02B | Buy |
1,430,370
+244,882
| +21% | +$206M | 0.07% | 247 |
|
|
2024
Q3 | $1.25B | Sell |
1,185,488
-155,810
| -12% | -$173M | 0.09% | 199 |
|
|
2024
Q2 | $1.41B | Buy |
1,341,298
+1,799
| +0.1% | +$1.74M | 0.11% | 171 |
|
|
2024
Q1 | $1.29B | Buy |
1,339,499
+199,980
| +18% | +$190M | 0.1% | 188 |
|
|
2023
Q4 | $1B | Buy |
1,139,519
+168,562
| +17% | +$139M | 0.09% | 211 |
|
|
2023
Q3 | $799M | Buy |
970,957
+25,792
| +3% | +$20.3M | 0.08% | 237 |
|
|
2023
Q2 | $679M | Buy |
945,165
+32,889
| +4% | +$25.4M | 0.07% | 275 |
|
|
2023
Q1 | $750M | Buy |
912,276
+22,898
| +3% | +$17.3M | 0.08% | 243 |
|
|
2022
Q4 | $642M | Buy |
889,378
+89,081
| +11% | +$65.7M | 0.07% | 278 |
|
|
2022
Q3 | $551M | Buy |
800,297
+42,253
| +6% | +$26.6M | 0.08% | 251 |
|
|
2022
Q2 | $448M | Buy |
758,044
+299,537
| +65% | +$195M | 0.06% | 321 |
|
|
2022
Q1 | $320M | Sell |
458,507
-77,525
| -14% | -$49M | 0.04% | 389 |
|
|
2021
Q4 | $339M | Buy |
536,032
+41,339
| +8% | +$25.4M | 0.04% | 393 |
|
|
2021
Q3 | $299M | Sell |
494,693
-11,228
| -2% | -$6.97M | 0.04% | 398 |
|
|
2021
Q2 | $283M | Sell |
505,921
-82,457
| -14% | -$41.8M | 0.04% | 428 |
|
|
2021
Q1 | $278M | Buy |
588,378
+41,041
| +7% | +$20M | 0.04% | 382 |
|
|
2020
Q4 | $264M | Buy |
547,337
+196,601
| +56% | +$106M | 0.04% | 381 |
|
|
2020
Q3 | $196M | Sell |
350,736
-9,476
| -3% | -$5.75M | 0.04% | 392 |
|
|
2020
Q2 | $225M | Buy |
360,212
+24,864
| +7% | +$14.1M | 0.05% | 321 |
|
|
2020
Q1 | $164M | Sell |
335,348
-125,581
| -27% | -$51.8M | 0.04% | 357 |
|
|
2019
Q4 | $173M | Buy |
460,929
+53,501
| +13% | +$18M | 0.04% | 411 |
|
|
2019
Q3 | $113M | Buy |
407,428
+106,547
| +35% | +$31.5M | 0.03% | 519 |
|
|
2019
Q2 | $94.2M | Sell |
300,881
-20,137
| -6% | -$6.7M | 0.03% | 574 |
|
|
2019
Q1 | $132M | Sell |
321,018
-285,114
| -47% | -$117M | 0.04% | 455 |
|
|
2018
Q4 | $226M | Buy |
606,132
+141,529
| +30% | +$51.8M | 0.07% | 295 |
|
|
2018
Q3 | $188M | Buy |
464,603
+192,236
| +71% | +$73.2M | 0.05% | 371 |
|
|
2018
Q2 | $94M | Buy |
272,367
+1,127
| +0.4% | +$352K | 0.03% | 601 |
|
|
2018
Q1 | $93.4M | Sell |
271,240
-26,852
| -9% | -$9.34M | 0.03% | 618 |
|
|
2017
Q4 | $112M | Sell |
298,092
-159,492
| -35% | -$64.6M | 0.03% | 542 |
|
|
2017
Q3 | $205M | Sell |
457,584
-52,672
| -10% | -$25.1M | 0.06% | 305 |
|
|
2017
Q2 | $251M | Buy |
510,256
+211,038
| +71% | +$92.4M | 0.08% | 278 |
|
|
2017
Q1 | $116M | Sell |
299,218
-63,987
| -18% | -$23.7M | 0.04% | 504 |
|
|
2016
Q4 | $133M | Buy |
363,205
+52,658
| +17% | +$20M | 0.04% | 437 |
|
|
2016
Q3 | $125M | Buy |
310,547
+17,023
| +6% | +$6.83M | 0.04% | 464 |
|
|
2016
Q2 | $103M | Sell |
293,524
-47,296
| -14% | -$18.2M | 0.04% | 498 |
|
|
2016
Q1 | $123M | Buy |
340,820
+19,156
| +6% | +$7.89M | 0.05% | 418 |
|
|
2015
Q4 | $175M | Sell |
321,664
-86,190
| -21% | -$46.7M | 0.06% | 320 |
|
|
2015
Q3 | $190M | Sell |
407,854
-327,098
| -45% | -$176M | 0.07% | 299 |
|
|
2015
Q2 | $375M | Buy |
734,952
+170,045
| +30% | +$83M | 0.13% | 183 |
|
|
2015
Q1 | $255M | Buy |
564,907
+136,295
| +32% | +$57.8M | 0.09% | 252 |
|
|
2014
Q4 | $176M | Buy |
428,612
+73,233
| +21% | +$28.8M | 0.06% | 327 |
|
|
2014
Q3 | $128M | Buy |
355,379
+31,025
| +10% | +$10.4M | 0.05% | 417 |
|
|
2014
Q2 | $91.6M | Buy |
324,354
+79,956
| +33% | +$23.7M | 0.04% | 544 |
|
|
2014
Q1 | $73.4M | Sell |
244,398
-87,175
| -26% | -$26.9M | 0.03% | 580 |
|
|
2013
Q4 | $91.3M | Buy |
331,573
+141,159
| +74% | +$40.6M | 0.04% | 489 |
|
|
2013
Q3 | $59.6M | Sell |
190,414
-39,809
| -17% | -$10.5M | 0.03% | 602 |
|
|
2013
Q2 | $51.8M | Buy |
+230,223
| New | +$53.6M | 0.03% | 630 |
|
Other funds holding REGN
Morgan Stanley's REGN Position: Q2 2026 in Review
Morgan Stanley increased its Regeneron Pharmaceuticals (REGN) stake by 5.9% in Q2 2026, buying an estimated $53.4M and bringing the position to 1,397,712 shares worth $872M. The position accounts for 0.05% of the portfolio, ranked #362.
Morgan Stanley first reported a position in REGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.41B in Q2 2024. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Morgan Stanley held 1,397,712 shares of Regeneron Pharmaceuticals worth $872M as of Q2 2026.
- Morgan Stanley bought 78,383 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $53.4M.
- Regeneron Pharmaceuticals made up 0.05% of Morgan Stanley's portfolio in Q2 2026, its #362 holding.
- Morgan Stanley first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- Morgan Stanley's Regeneron Pharmaceuticals position peaked at $1.41B in Q2 2024.
- 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.